PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-16.26%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-26.53%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
22.34%
Positive EBIT growth while AVGO is negative. John Neff might see a substantial edge in operational management.
-80.00%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-84.11%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-88.89%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-88.89%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
-0.47%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-0.62%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
0.47%
Dividend growth of 0.47% while AVGO is flat. Bruce Berkowitz would see if this can become a bigger advantage long term.
-77.55%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-80.02%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
28.28%
10Y CAGR of 28.28% while AVGO is zero. Bruce Berkowitz would see if incremental growth can widen into a significant edge.
-3.43%
Negative 5Y CAGR while AVGO stands at 0.00%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-22.22%
Negative 3Y CAGR while AVGO stands at 0.00%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
45.03%
OCF/share CAGR of 45.03% while AVGO is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
-13.19%
Negative 5Y OCF/share CAGR while AVGO is at 0.00%. Joel Greenblatt would question the firm’s operational model or cost structure.
-43.98%
Negative 3Y OCF/share CAGR while AVGO stands at 0.00%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-91.64%
Negative 10Y net income/share CAGR while AVGO is at 0.00%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-93.70%
Negative 5Y net income/share CAGR while AVGO is 0.00%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-96.39%
Negative 3Y CAGR while AVGO is 0.00%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
72.90%
Equity/share CAGR of 72.90% while AVGO is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
3.59%
Equity/share CAGR of 3.59% while AVGO is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
1.88%
Equity/share CAGR of 1.88% while AVGO is zero. Bruce Berkowitz sees if minor gains can snowball into a bigger lead soon.
435.74%
Dividend/share CAGR of 435.74% while AVGO is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
417.97%
Dividend/share CAGR of 417.97% while AVGO is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
265.17%
3Y dividend/share CAGR of 265.17% while AVGO is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.
23.22%
AR growth of 23.22% while AVGO is zero. Bruce Berkowitz wonders if the firm’s additional AR is warranted by strong revenue or potential risk.
-20.15%
Inventory is declining while AVGO stands at 0.00%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-3.38%
Negative asset growth while AVGO invests at 0.00%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-0.78%
We have a declining book value while AVGO shows 0.00%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
-10.44%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-15.75%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.